Uveal melanoma ranks as the most common type of intraocular tumor in adults globally, with its metastatic cancer holding a poor prognosis and a survival rate of around 10% at 2 years. Recent data reflects that at least 50% of the patients suffering from high-risk primary uveal melanoma are likely to develop a recurrence post-treatment of the primary tumor. Thus, due to the aggressive nature of this eye cancer and the availability of limited treatment options in advanced stages, there is an increased focus on the development of effective drugs to combat the disease.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to uveal melanoma.
The risk factors linked with uveal melanoma include increasing age and fair complexion. Chemotherapy and immunotherapy are common treatments for the disease. The first FDA-approved therapy for unresectable or metastatic uveal melanoma is Kimmtrak (tebentafusp-tebn). This drug works by targeting a lineage antigen (gp100) present in melanocytes and melanoma. With the rising investments in research and development of new treatments for rare forms of eye cancers, the drug pipeline for uveal melanoma is poised to lead to the market entry of promising treatment options.
This drug is under investigation to treat patients with primary indeterminate lesions or small choroidal melanoma, a type of uveal melanoma. It is in Phase 3 of a randomized, masked, controlled study sponsored by Aura Biosciences.
Lifileucel (LN-144)
Currently, in Phase 1 of an open-label study, Lifileucel, a cryopreserved autologous tumor-infiltrating lymphocyte (TIL) therapy, is under investigation for the treatment of patients with metastatic uveal melanoma.
This product will be delivered within 3-5 business days.
Report Coverage
The Uveal Melanoma Drug Pipeline Insight Report by the publisher gives comprehensive insights into uveal melanoma drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for uveal melanoma. The report includes the analysis of over 100 pipeline drugs and 50+ companies . The uveal melanoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from uveal melanoma.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to uveal melanoma.
Uveal Melanoma Drug Pipeline Outlook
Uveal melanoma (also known as choroidal melanoma) is the most commonly occurring primary intraocular malignancy in adults. In the United States, there were 3490 new cases of uveal melanoma in 2023. Although the incidence of this disease has remained nearly constant over the last few years, the main challenge of uveal melanoma lies in the metastatic stage, with survival rates of the patients dropping to only 16%.The risk factors linked with uveal melanoma include increasing age and fair complexion. Chemotherapy and immunotherapy are common treatments for the disease. The first FDA-approved therapy for unresectable or metastatic uveal melanoma is Kimmtrak (tebentafusp-tebn). This drug works by targeting a lineage antigen (gp100) present in melanocytes and melanoma. With the rising investments in research and development of new treatments for rare forms of eye cancers, the drug pipeline for uveal melanoma is poised to lead to the market entry of promising treatment options.
Uveal Melanoma - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of unresectable melanoma drugs based on several segmentations including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
By Route of Administration
- Oral
- Parenteral
- Others
Uveal Melanoma - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for uveal melanoma. There are around 26 drugs in phase II for uveal melanoma.Uveal Melanoma - Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under uveal melanoma pipeline analysis include monoclonal antibodies, peptides, polymers, small molecules, and gene therapy. The choice of treatment depends on multiple factors including the size and location of the tumor, the patient's health and age, and whether the tumor has spread to other parts of the body.Uveal Melanoma Clinical Trials Therapeutic Assessment - Competitive Dynamics
The report for the uveal melanoma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in uveal melanoma clinical trials:- Novartis Pharmaceuticals
- TriSalus Life Sciences, Inc.
- IDEAYA Biosciences
- Kezar Life Sciences, Inc.
- Fusion Pharmaceuticals Inc.
- Xencor, Inc.
- Immatics US, Inc.
- Aura Biosciences
- OncoNano Medicine, Inc.
- Modulation Therapeutics, Inc.
Uveal Melanoma - Emerging Drugs Profile
Major drugs currently in the pipeline are as follows:
Belzupacap Sarotalocan (AU-011)This drug is under investigation to treat patients with primary indeterminate lesions or small choroidal melanoma, a type of uveal melanoma. It is in Phase 3 of a randomized, masked, controlled study sponsored by Aura Biosciences.
Melatonin
Melatonin tablet (20 mg) is in a Phase 3 randomized trial, where its efficacy in preventing or delaying the development of metastases in around 100 patients diagnosed with primary uveal melanoma will be tested.Darovasertib
In Phase 2 multi-center open-label study, this drug is being assessed for its treatment efficacy in primary uveal melanoma patients. Sponsored by IDEAYA Biosciences, the trial is estimated to enroll 82 participants.Lifileucel (LN-144)
Currently, in Phase 1 of an open-label study, Lifileucel, a cryopreserved autologous tumor-infiltrating lymphocyte (TIL) therapy, is under investigation for the treatment of patients with metastatic uveal melanoma.
Reasons To Buy This Report
The Uveal Melanoma Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for uveal melanoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within uveal melanoma pipeline insights.Key Questions Answered in the Uveal Melanoma - Pipeline Insight Report
- What is the current landscape of uveal melanoma pipeline drugs?
- How many companies are developing uveal melanoma drugs?
- How many phase III and phase IV drugs are currently present in uveal melanoma pipeline drugs?
- Which companies/institutions are leading the uveal melanoma drug development?
- What is the efficacy and safety profile of uveal melanoma pipeline drugs?
- What are the opportunities and challenges present in the uveal melanoma drug pipeline landscape?
- Which company is conducting major trials for uveal melanoma drugs?
- What geographies are covered for uveal melanoma clinical trials?
- What are emerging trends in uveal melanoma clinical trials?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Uveal Melanoma
4 Patient Profile: Uveal Melanoma
5 Uveal Melanoma: Epidemiology Snapshot
6 Uveal Melanoma: Market Dynamics
7 Uveal Melanoma: Key Facts Covered
8 Uveal Melanoma, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Uveal Melanoma Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Uveal Melanoma Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Uveal Melanoma Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Uveal Melanoma Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Uveal Melanoma, Key Drug Pipeline Companies
